Analybax reports third quarter results for 2021

by time news

Began the process of planning and building a new plant in the cGMP standard for Allocetra production.

An existing cash position is planned to meet all of the company’s needs for the years 2022-2023 including running the planned clinical trials in sepsis, corona and oncology, and building the new manufacturing plant.

Clinical deadlines for evaluating the company: Results of Phase II experiment in sepsis in the fourth quarter of 2022 and results of Phase IIb in Corona in the fourth quarter of 2022 or first quarter of 2023.

Analybax Therapeutics (Nasdaq: ENLV) reports that it submitted its financial results for the third quarter ended September 30, 2021 to the U.S. Securities and Exchange Commission on November 19, 2021.

“We are moving forward towards 2022 with a strong balance sheet, an expanded management team and convincing clinical and preclinical data, which we believe illustrate the potential of Allocetra as a next-generation cellular treatment for infectious, inflammatory and oncological diseases,” he noted. Dr. Oren Hershkovich, CEO of Annelebks. “Our ongoing experiments at Sepsis and Corona have recently received approval to expand to sites in Spain, a fact that places us in expanding the impact of our treatments alongside important regulatory verification of our trial designs and production process. We need to be prepared for larger clinical trials and the possible start of commercial activities. “

Dr. Hershkowitz continued, “Along with regulatory and corporate progress, we have continued to advance the Oncology Program for the treatment of solid tumors towards the start of 2 planned clinical trials. Through the progress of these trials, we aim to clinically demonstrate the potential of Allocetra to integrate synergistically with currently available cancer therapies and to improve response rates among difficult-to-treat cancer patients. Looking ahead, we expect that our solid, sepsis and corona growth plans will gain momentum as we work to address life-threatening situations through the clinical development of Allocetra. ”

READ Also:  The head of the US Treasury announced the appropriateness of financial pressure on the Russian Federation because of Ukraine

.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.